Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
Their vaccine has been tested on 43,538 participants, with 42 per cent having diverse backgrounds, and no serious safety concerns have been observed. Of these participants, 94 who received the vaccine were protected against the disease 28 days after the initiation of the vaccination.